ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020
Malignant mesothelioma in situ: morphologic features and clinical outcome.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 112 citations in OpenAlex.
- What's new in neoplastic pulmonary pathology 2026: updates on grading, staging and molecular testing.Journal of pathology and translational medicine · 2026Article
- Consensus Guideline for the Management of Peritoneal Mesothelioma.Annals of surgical oncology · 2026Review
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Isolated primary pericardial sarcomatoid mesothelioma: a case report.Frontiers in oncology · 2026Article
- Review
- DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.Cancer immunology, immunotherapy : CII · 2025Article
- Review
- Mesothelioma: morphologic and immunohistochemical findings.Pathologie (Heidelberg, Germany) · 2024Review
- Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?Current oncology (Toronto, Ont.) · 2024Review
- ERS International Congress 2023: highlights from the Thoracic Oncology Assembly.ERJ open research · 2024Article
- Peritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years.Virchows Archiv : an international journal of pathology · 2023Article
- Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.Diagnostic pathology · 2023Article
- REDCap and the National Mesothelioma Virtual Bank-a scalable and sustainable model for rare disease biorepositories.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Diffuse malignant peritoneal mesothelioma presenting as small bowel obstruction.Radiology case reports · 2023Article
- Pleural Neoplasms-What Could MRI Change?Cancers · 2023Review
- Usefulness of malignant pleural effusion for early cytological diagnosis of mesotheliomaOncology letters · 2022Article
- Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma.Diagnostics (Basel, Switzerland) · 2022Review
- New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications.Diagnostics (Basel, Switzerland) · 2022Review
- Malignant pleural mesothelioma in situ.Interactive cardiovascular and thoracic surgery · 2022Article
- A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss.Respirology case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The existence of an in situ phase of malignant mesothelioma has long been postulated but until recently has been impossible to prove. Here we describe ten patients with mesothelioma in situ, defined by a single layer of surface mesothelial cells showing loss of BAP1 nuclear immunostaining, no evidence of tumor by imaging and/or by direct examination of the pleura/peritoneum, and no invasive mesothelioma developing for at least 1 year. Nine cases were pleural and one peritoneal. Most patients were biopsied for repeated effusions of unknown etiology; in two patients mesothelioma in situ was found incidentally in lung cancer resections. In addition to surface mesothelium with BAP1 loss, one case had a surface papillary proliferation with BAP1 loss, and two cases had a small (few millimeter) nodule with BAP1 loss. CDKN2A was deleted by FISH in one of eight cases. Methylthioadenosine phosphorylase showed partial loss in the surface mesothelium by immunohistochemistry in three cases. Invasive malignant mesothelioma developed in seven patients with time between biopsy and invasive disease from 12 to 92 (median 60) months. Invasive mesothelioma has not developed in the other three patients at 12, 57, and 120 months, but the latter patient, who has pleural plaques, still has repeated pleural effusions, probably representing a so-called "benign asbestos effusion." We conclude that mesothelioma in situ, as diagnosed using the criteria outlined above, is associated with a high risk of developing invasive mesothelioma, but typically over a relatively protracted time, so that curable interventions maybe possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.